Venatorx Pharmaceuticals Announces First Patient Dosed in Phase I Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

Venatorx Pharmaceuticals announced that the first patient was dosed in a Phase I clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus infection.